THE WOODLANDS, Texas, Aug. 26, 2004 (PRIMEZONE) -- Power3 Medical Products, Inc. (OTCBB:PWRM) a leading proteomics company, announces that Dr. Ira L. Goldknopf, Chief Scientific Officer, will report on the company's discovery of a biomarker for early detection of breast cancer at the Cambridge Healthtech Institute's Second Annual Protein Biomarkers Conference. The conference will be held in Philadelphia, Pennsylvania at the Wyndham Hotel, September 8th through 10th, and will cover the latest developments in the application of proteomics to diagnostics, drug development, and the monitoring of drug toxicity.
The Second Annual Protein Biomarkers meeting provides an overview of the discovery and validation of protein biomarkers. Protein biomarkers offer great potential to detect and describe disease processes in patients, at times with a more accurate representation of the biological state of the patient than genomics or gene expression biomarkers. The meeting will provide case studies of protein biomarker applications, a comprehensive overview of proteomic biomarker discovery and assay development, as well as facilitate discussion on the "ideal" protein biomarkers and their advantages.
Power3 Medical's results are outlined in an abstract for the conference entitled "A Newly Identified Biomarker for Early Detection of Breast Cancer," and Dr. Goldknopf will be displaying this information at the conference. The abstract discusses a particular breast cancer protein biomarker that Power3 has identified in nipple aspirate fluid (NAF). According to Dr. Goldknopf, "The early detection of breast cancer is particularly important because of the high degree of genetic instability in this disease. Our preliminary data suggest that a substantial decrease in this protein biomarker has the potential to be a more sensitive indication of breast cancer than mammography. The function of this protein suggests that it might also be a key player in the first line of defense against genetic instability, suggesting that its loss may play a very early role in the development of breast cancer."
For more information about the Cambridge Healthtech Institute's Second Annual Protein Biomarkers Conference please visit www.ProteinBiomarkers.com.
About Power3 Medical Products Inc.
Power3 Medical Products is a leading proteomics company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases. The Company's patent pending technologies are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The Company's identified protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease.
Safe Harbor Statement
All statements other than statements of historical fact included in this press release are "forward-looking statements." The forward-looking statements, including statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements (i.e., future operational results and sales) are subject to assumptions and beliefs based on current information known to the Company and factors that are subject to uncertainties, risk and other influences, which are outside the Company's control, and may yield results differing materially from those anticipated.